Progenics Pharma (PGNX) Misses Q1 EPS by 5c

Progenics Pharma (NASDAQ: PGNX) reported Q1 EPS of ($0.18), $0.05 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $2.5 million versus the consensus estimate of $3.27 million.

For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.

You May Also Be Interested In

• Gordon Haskett cuts TJX Companies rating to Accumulate
• Advance Auto Parts (AAP) Tops Q2 EPS by 22c; lifrs profit guidance
• Dingdong (DDL) Reports Q2 EPS of RMB0.90